NTLA(Intellia Therapeutics, Inc.) · 财务报表

NTLA(Intellia Therapeutics, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2021-12-31FY 截至 2022-12-31FY 截至 2023-12-31FY 截至 2024-12-31FY 截至 2025-12-31
营业收入$33.05M$52.12M$36.27M$57.88M$67.67M
毛利润$33.05M————
营业利润−$267.85M−$458.16M−$515.29M−$534.26M−$440.99M
净利润−$267.89M−$474.19M−$481.19M−$519.02M−$412.69M
经营现金流−$225.03M−$333.29M−$394.09M−$348.88M−$394.74M
自由现金流−$237.79M−$346.85M−$408.07M−$354.66M−$395.87M
摊薄每股收益$-3.78$-6.16$-5.42$-5.25$-3.81

Intellia Therapeutics, Inc. NTLA